The Hypertension Optimal Treatment (HOT) study: Implications for hypertension management and the J-shape curve

被引:0
作者
Schulman, S [1 ]
Brunton, S
Shepard, DS
Jacobs, RP
Gerstenblith, G
Wilson, M
Wagner, SL
机构
[1] Clin Commun Inc, Educ & Sci Affairs, Greenwich, CT USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Johns Hopkins Univ Hosp, Coronary Care Unit, Baltimore, MD 21287 USA
[4] Brandeis Univ, Heller Sch, Waltham, MA 02254 USA
[5] NYU, Univ MSO, New York, NY USA
[6] Johns Hopkins Univ Hosp, Div Cardiol, Baltimore, MD 21287 USA
[7] HealthCore Inc, Newark, DE USA
[8] Sanger Clin PA, Charlotte, NC USA
关键词
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Epidemiologic surveys in the United States indicate that only a minority of patients with hypertension have adequate blood pressure control on therapy. Concern over the J-curve may be leading physicians to undertreat hypertension. The existence of a J-curve, the increase in cardiovascular mortality when the blood pressure is lowered beyond the threshold for myocardial perfusion, has been actively debated. The Hypertension Optimal Treatment (HOT) study was designed to address the following concerns with respect to antihypertensive treatment: (1) How aggressively should blood pressure be towered? (2) What is the optimum target pressure in terms of minimum cardiovascular risk? and (3) Does aspirin therapy provide added cardiovascular benefits in patients being treated for hypertension? In the HOT study, 18,790 patients were randomized to diastolic blood pressure target groups of less than or equal to 90 mm Hg, less than or equal to 85 mm Hg, or less than or equal to 80 mm H and further randomized to 75 mg/day aspirin or placebo. Felodipine was given as baseline therapy with the addition of other agents according to a five-step regimen. A major achievement in the trial was a greater than 20-mm Hg reduction in blood pressure in all three target blood pressure groups. The incidence of cardiovascular morbidity and mortality was low in HOT, in comparison with previous trials. Event: rates, except for myocardial infarction (MI), were similar in all three target blood pressure groups, but aggressive treatment afforded significant cardioprotection to diabetic patients. The optimum diastolic blood pressure in terms of minimum cardiovascular risk was between 80 and 85 mm Hg. Coadministration of low-dose aspirin provided added cardiovascular benefit without significantly increasing the risk of fatal bleeding. However, because of the close degree of blood pressure reduction among the three target blood pressure groups in this study, the issue of the J-curve could not be resolved.
引用
收藏
页码:S733 / S740
页数:8
相关论文
共 12 条
  • [1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [2] [Anonymous], 1993, Blood Press, V2, P62
  • [3] TRENDS IN THE PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERTENSION IN THE ADULT US POPULATION - DATA FROM THE HEALTH EXAMINATION SURVEYS, 1960 TO 1991
    BURT, VL
    CUTLER, JA
    HIGGINS, M
    HORAN, MJ
    LABARTHE, D
    WHELTON, P
    BROWN, C
    ROCCELLA, EJ
    [J]. HYPERTENSION, 1995, 26 (01) : 60 - 69
  • [4] COLLINS R, 1994, TXB HYPERTENSION, P1156
  • [5] CRUICKSHANK JM, 1987, LANCET, V1, P581
  • [6] FLETCHER AE, 1992, NEW ENGL J MED, V326, P251
  • [7] Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial
    Hansson, L
    Zanchetti, A
    Carruthers, SG
    Dahlöf, B
    Elmfeldt, D
    Julius, S
    Ménard, J
    Rahn, KH
    Wedel, H
    Westerling, S
    [J]. LANCET, 1998, 351 (9118) : 1755 - 1762
  • [8] J-curve not burned off by HOT study
    Kaplan, N
    [J]. LANCET, 1998, 351 (9118) : 1748 - 1749
  • [9] LISKOWSKY DR, 1991, JAMA-J AM MED ASSOC, V265, P3225
  • [10] THE RISK OF MYOCARDIAL-INFARCTION ASSOCIATED WITH ANTIHYPERTENSIVE DRUG THERAPIES
    PSATY, BM
    HECKBERT, SR
    KOEPSELL, TD
    SISCOVICK, DS
    RAGHUNATHAN, TE
    WEISS, NS
    ROSENDAAL, FR
    LEMAITRE, RN
    SMITH, NL
    WAHL, PW
    WAGNER, EH
    FURBERG, CD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (08): : 620 - 625